Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors
This is a FTiH, Phase 1 IIT to evaluate the safety, feasibility, cellular kinetics (CK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of AZD6422 in adult participants with advanced or metastatic CLDN18.2+ GI tumors.
Gastrointestinal Tumors
BIOLOGICAL: AZD6422 CLDN18.2 CAR-T product
Incidence of treatment-emergent AEs, AESIs, and SAEs., Incidence of treatment-emergent AEs, AESIs, and SAEs., Within 24 months of the last AZD6422 infusion or the start of a new anticancer treatment|Occurrence of Dose limiting toxicity., Occurrence of DLTs (Dose limiting toxicity)., Within 28 days after the first infusion|Changes from baseline in vital signs, laboratory parameters, physical examination, and 12-lead ECG., Changes from baseline in vital signs, laboratory parameters, physical examination, and 12-lead ECG., Within 28 days after the first infusion
ORR, The proportion of participants who have a confirmed CR or confirmed PR as determined by the investigator at local site per RECIST v1.1., 24 months post AZD6422 infusion|DoR, The time from first documented confirmed response until date of documented progression of disease per RECIST v1.1 as determined by investigator at local site or death due to any cause., 24 months post AZD6422 infusion|DCR, The proportion of participants who have a confirmed CR, confirmed PR, or who have SD per RECIST v1.1 as assessed by the investigator at local site and derived from the raw tumor data for at least 11 weeks after infusion date., 24 months post AZD6422 infusion|PFS, Time from infusion date until progression per RECIST v1.1 as assessed by the investigator at local site, or death due to any cause., 24 months post AZD6422 infusion
Qualified researchers can request access to anonymized individual patient-level data from sponsor or the collaborator group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the sponsor disclosure commitment. Yes, indicates that sponsors are accepting requests for IPD, but this does not mean all requests will be shared.